AI-generated from publicly available materials.Johnson & Johnson MedTech has unveiled Monarch Quest 3, a new software update for its robotic bronchoscopy platform, following FDA 510(k) clearance. This marks the fourth enhancement to the Monarch system in just 18 months, reflecting the company's commitment to advancing lung cancer diagnostics.
The Monarch platform is designed to assist clinicians with real-time visualization and precise control during lung biopsies. The latest software iteration introduces significant improvements such as enhanced registration capabilities and a 3D compass overlay, which aids in scope-tip orientation, particularly as patient anatomy changes. Additionally, the software leverages AI for more accurate nodule segmentation, enhancing pre-procedural planning.
Monarch Quest 3 also increases compatibility with existing Cone-Beam CT imaging systems, addressing challenges related to discrepancies between pre-operative imaging and actual anatomy during procedures. This advancement is part of Johnson & Johnson's ongoing strategy to innovate in robotic bronchoscopy, aiming to improve patient outcomes in lung cancer care.
As competition intensifies in the robotic bronchoscopy market, with other companies like Noah Medical and Intuitive launching their own software advancements, Johnson & Johnson's proactive enhancements to the Monarch platform underscore its commitment to maintaining leadership in this critical area of medical technology.